会议纪要要点 公司及行业概述 1. **公司名称及会议主题**：Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 5th Annual Evercore ISI HealthCONx Conference，2022年11月29日11:45 AM ET。[doc id='1'] 2. **参会人员**：Regeneron公司研发执行副总裁Neil Stahl、免疫肿瘤和双特异性项目负责人John Lin、投资者关系部Ryan Crowe等。[doc id='2'] 3. **讨论重点**：双特异性抗体和ADC药物组合、高剂量EYLEA和IRA，以及行业动态。[doc id='2'] 双特异性抗体 1. **CD28双特异性抗体**：针对PSMA和前列腺癌的研究正在进行中，旨在提高治疗效果。[doc id='3'] 2. **安全性问题**：目前正在进行不同剂量水平的研究，以减轻潜在的免疫相关副作用。[doc id='7'] 3. **疗效数据**：初步数据显示，PSMAxCD28单药治疗在初始治疗期间肿瘤标志物水平升高，但与Libtayo联合使用后，PSA水平迅速下降。[doc id='12'] 4. **未来计划**：预计在2023年上半年公布更多关于初始患者和后续患者的数据。[doc id='14'] 5. **MET双特异性抗体**：在MET基因扩增或过表达的肺癌患者中显示出疗效，且毒性较低。[doc id='16'] 6. **METxMET ADC**：正在研究将ADC药物与METxMET双特异性抗体结合，以提高疗效。[doc id='18'] 高剂量EYLEA 1. **PHOTON和PULSAR研究**：在PULSAR研究中，8 mg剂量组的疗效优于2 mg剂量组。[doc id='20'] 2. **IRA**：IRA的推出可能会影响高剂量EYLEA的市场策略，但具体影响尚不明确。[doc id='22] 3. **J-code**：如果IRA获得批准，将获得新的J-code，从而影响定价策略。[doc id='26] 其他 1. **Dupixent**：在多个适应症中取得显著进展，包括特应性皮炎、哮喘、鼻息肉和嗜酸性食管炎。[doc id='28] 2. **COPD**：COPD市场潜力巨大，但需要更多数据来评估Dupixent的疗效。[doc id='31] 3. **Alzheimer's disease**：与Alnylam合作开发siRNA疗法，针对APP蛋白，有望治疗阿尔茨海默病。[doc id='37]

Regeneron Pharmaceuticals, Inc. (AAPL) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - President, Chief Scientific Officer Marion McCourt - Executive Vice President, Head of Commercial Robert Landry - Executive Vice President, Chief Financial Officer Conference Call Participants Evan Seigerman - BMO Tyler Van Buren - Cowen Salveen Richter - Goldman Sac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 1 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - President, Chief Scientific Officer Marion McCourt - Executive Vice President, Head of Commercial Robert Landry - Executive Vice President, Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Evan Seigerman - BMO Capital Markets Tyler ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-344 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-34 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-3444607 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2021 Results Conference Call February 4, 2022 8:30 AM ET Company Participants Mark Hudson - Director, IR Dr. Len Schleifer - Co-Founder, President, CEO & Executive Director Dr. George Yancopoulos - Co-Founder, President & Chief Scientific Officer Marion McCourt - EVP and Head of Commercial Bob Landry - EVP & CFO Conference Call Participants Evan Seigerman - BMO Carter Gould - Barclays Tyler Van Buren - Cowen Salveen Richter - Goldman Sachs Ronny Gal - Allianc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Class of Common Stock Number of Shares Class A Stock, $.001 par value 1,848,970 Common Stock, $.001 par value 104,543,424 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission F ...